Navigation Links
Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008

CRANBURY, N.J., Feb. 7 /PRNewswire-FirstCall/ -- Amicus Therapeutics Inc. (Nasdaq: FOLD), today announced that John F. Crowley, President and Chief Executive Officer, will present a corporate update at BIO CEO & Investor Conference 2008 in New York, NY on Monday, February 11, 2008 at 12:30 pm (Eastern Standard Time) at the Waldorf-Astoria Hotel.

The presentation will be webcast live and may be accessed by visiting Amicus' website at A replay of the webcast will also be available on the Company's website until February 25, 2008.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. The Company has completed Phase 1 clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

Amicus cautions you that statements included in this press release that are not a description of historical facts are "forward-looking statements" within the meaning of Section 21E of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the potential progress and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the effect of the completion of the Phase 2 clinical trial for Amigal(TM) for the treatment of Fabry disease, the plans for the Phase 3 clinical trial for Amigal, the Phase 2 clinical trials for Plicera(TM) for the treatment of Gaucher disease, and the effect of the completion of the Phase 1 clinical trials for AT2220 for the treatment of Pompe disease may not proceed in the timeframes or in the manner Amicus expects or at all. Further, the results of earlier clinical trials may not be predictive of future results; Amicus and its licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks detailed in the public filings of Amicus with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date hereof. All forward- looking statements are qualified in their entirety by this cautionary statement and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


SOURCE Amicus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
11. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Post Your Comments:
(Date:12/1/2015)... 1, 2015 Vancouver ... lancet that features Owen Mumford,s unique Comfort Zone Technology®. ... Unistik® Touch is a touch activated lancet that features ... Owen Mumford, a leading medical device manufacturer, today unveils ... available initially in the US before expanding out to ...
(Date:12/1/2015)... , Dec. 1, 2015 Today the ... in Seattle,s South Lake Union ... corner of Mercer Street and Westlake Avenue North, the ... the Allen Institute for Brain Science and the Allen ... , philanthropist and founder of the Allen Institute. "We ...
(Date:12/1/2015)... Dec. 1, 2015 Researchers at the Broad ... for Brain Research at MIT have engineered changes to ... down on "off-target" editing errors. The refined technique addresses ... of genome editing. Science , Feng ... of the approximately 1,400 amino acids that make up ...
(Date:12/1/2015)... Bioscience, a company focused on synthetic DNA, today announced that ... as one of Foreign Policy,s 100 Leading Global ... life . Each year, Foreign Policy selects the ... changed lives and are shaping the world. ... be recognized among these incredible global leaders," said Leproust. "At ...
Breaking Biology Technology:
(Date:12/1/2015)... Synaptics Incorporated (NASDAQ: SYNA ), the ... new agreement with Nok Nok Labs ™ ... environments that combine FIDO Certified ™ Synaptics and ... of FIDO certification for Synaptics, customers. Using Nok Nok ... verify FIDO enabled devices in real-world authentication scenarios. ...
(Date:11/30/2015)... , Nov. 30, 2015  BIOCLAIM announced ... finalist in this year,s Fierce Innovation Awards:  Healthcare Edition, ... FierceHealthIT , FierceHealthcare , ... as a finalist in the category of "Privacy ... --> --> ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... Fingerprint Sensors - Technology and Patent Infringement Risk Analysis" ... --> --> Fingerprint sensors using capacitive ... The fingerprint sensor vendor Idex forecasts an increase of ... mobile devices and of the fingerprint sensor market between ...
Breaking Biology News(10 mins):